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Abstract: Eighty years ago Drury & Szent-Györgyi described the actions of adenosine, AMP (adenylic acid) and ATP 
(pyrophosphoric or diphosphoric ester of adenylic acid) on the mammalian cardiovascular system, skeletal muscle, intes-
tinal and urinary systems. Since then considerable insight has been gleaned on the means by which these compounds act, 
not least of which in the distinction between the two broad classes of their respective receptors, with their many subtypes, 
and the ensuing diversity in cellular consequences their activation invokes. These myriad actions are of course predicated 
on the release of the purines into the extracellular milieu, but, surprisingly, there is still considerable ambiguity as to how 
this occurs in various physiological and pathophysiological conditions. In this review we summarise the release of ATP 
and adenosine during seizures and cerebral ischemia and discuss mechanisms by which the purines adenosine and ATP 
may be released from cells in the CNS under these conditions. 
INTRODUCTION 
  It is now beyond dispute that purine compounds such as 
adenosine and ATP are released from cells of the mammal-
ian  central  nervous  system  and  exert  powerful  actions  on 
neuronal function via a variety of cell surface receptors. To 
have arrived at this conclusion required work spanning eight 
decades. In this review we provide an account of the studies 
that demonstrated the release of purine compounds following 
physiological or pathological stimulation of brain tissue in 
vitro and in vivo and describe some of the possible conduits 
of purine release under these conditions. Although there is 
evidence for guanine nucleotide release in the central nerv-
ous  system,  most  likely  from  glial  cells,  and  extracellular 
conversion to guanosine [167], we shall restrict this review 
to adenosine and ATP. Molecular aspects of purinergic sig-
nalling are not covered in detail, but can be found in several 
excellent recent reviews [2,3,53,88,96,170,207,231], whilst a 
more systems-level understanding of the role of purines in 
the CNS can be found in other chapters of this Hot Topics 
issue of Current Neuropharmacology. 
ADENOSINE AND ATP AS NEUROMODULATORS 
  The possibility that the purines adenosine and ATP could 
influence neuronal function in the mammalian CNS was tan-
talizingly hinted at in Alan Drury & Albert Szent-Györgyi's 
seminal  study  [44]  during  which  they  reported  that  "The 
animal [guinea pig] immediately after the [sc] injection [of 
adenosine] appears normal, but within a minute or two de-
velops a panting respiration, becomes listless, and tends to 
lie quite still and on occasions to sleep.". 
  However, these scientists, one of whom (Drury) went on 
to become elected Fellow of the Royal Society (1937) and 
receive a Knighthood (1950), and the other to receive a No-
bel  Prize  (Szent-Györgyi;  Physiology  or  Medicine,  1937), 
could not state "…whether an action on the nervous system 
must  be  considered…"  as  responsible  for  the  adenosine- 
 
*Address correspondence to this author at Department of Biological Sci-
ences,  University  of  Warwick,  Coventry,  CV4  7AL,  UK;  Tel:  02476 
150591; Fax: 02476 523701; E-mail: b.g.frenguelli@warwick.ac.uk 
induced  somnolence,  given  the  profound  effects  on  blood 
pressure  and heart rate. Fast forward  eighty years and  the 
role of adenosine in sleep is firmly established [75,109] (see 
also Greene, this issue). 
  The  realisation  that  purines  were  major  players  in  the 
CNS  was  hard  won  in  the  ensuing  decades  and  emerged 
slowly in the 1960 and 70s after a series of largely negative 
findings  related  to  the  actions  of  iontophoretically-applied 
ATP  to neurones in  cortex and  spinal  cord [30,104]. This 
was  in  contrast  to  work  in  the  periphery,  spearheaded  
by Geoff Burnstock, which was more supportive of a role  
for  ATP  as  a  potential  neurotransmitter  [20,79],  although  
the concept that precious ATP, the cellular energy currency, 
might  be  released  from  cells  under  normal  circumstances 
was  heretical  and  fiercely  resisted  [21].  Subsequent  work  
by  John  Phillis  and  colleagues  indicated  that  ATP  and  
adenine  derivatives  such  as  adenosine  were  powerful  sup-
pressors of neuronal firing in the brain [156,157], an action 
we  now  attribute  to  the  dominant  role  of  the  adenosine  
A1 receptor.  
  These  early  studies  paved  the  way  for  what  we  now 
know that adenosine and ATP exert their unequivocal neuro-
transmitter and neuromodulator actions, both excitatory and 
inhibitory,  in  the  mammalian  CNS  via  a  large  variety  of 
purine receptors. These are divided into the P1 and P2 recep-
tors. P1 receptors are activated primarily by adenosine, but 
some (eg A3R) may also be activated by the immediate me-
tabolite of adenosine, inosine. Adenosine receptors, of which 
four are presently known - A1, A2A, A2B and A3, are all 7-
transmembrane  spanning  G-protein-coupled  receptors  with 
A1 and A3 primarily coupling to Gi/o and the A2 receptors 
coupling to Gs/olf [22,64,165]. It is through these receptors 
that adenosine modulates or "fine-tunes" synaptic transmis-
sion in the CNS (see Sebastião, this issue). 
  P2 receptors are sub-divided into P2X and P2Y groups 
[25]. P2X receptors  are  trimeric  ligand-gated ion  channels 
and presently comprise seven subtypes (P2X1-7), activated by 
ATP [88,96,170]. P2X receptors form functional receptors in 
various homo- and hetero-oligomeric assemblies of individ-
ual P2X subunits and all P2X channels are permeable to Na
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K
+  and  Ca
2+.  However  some  are  permeable  to  Cl
-,  whilst 
under certain conditions some subtypes undergo pore dila-
tion  and  become  permeable  to  larger  molecules  such  as 
NMDG
+, YO-PRO, glutamate and even ATP [53]. 
  P2Y  receptors,  like  P1  receptors  are  7-transmembrane 
spanning  G-protein-coupled  receptors  of  which  there  are 
eight  subtypes  (P2Y1,2,4,6,11,12,13,14).  The  P2Y  nomenclature 
lacks  several  members,  reflecting  either  the  existence  of 
nonmammalian  orthologs  or  receptors  having  some  P2Y 
receptor sequence similarity but no apparent response to nu-
cleotides. These receptors are designated as p2y [2]. 
  In the case of P2Y receptors the nature and order of po-
tency for nucleotides differs and includes the purines ATP, 
ADP, and the pyrimidines, UTP, UDP and UDP glucose as 
agonists at human P2Y receptors. [2]. A subdivision of P2Y 
receptors  has  been  proposed  based  on  phylogenetic  and 
structural similarities [1], one group comprising P2Y1,2,4,6,11 
and another containing P2Y12,13,14. Interestingly heteromers 
exist between P2Y1 and A1 [225-227] and P2Y2 and A1 re-
ceptors  [196],  whilst  functional  interactions  between  P2Y1 
and A1 are found in the brain [200,201]. These heteromers 
suggests  a  relationship  between  adenosine  and  ATP  more 
intimate than that predicted from one simply being a metabo-
lite of the other.  
  The actions of ATP and adenosine at these extracellular 
receptors  are  critically  dependent  on  the  release  of  these 
purines from cells. That this is self evident is obvious, but 
surprisingly, the release process remains mysterious in many 
instances and likely reflects the complexity of purine produc-
tion, metabolism and release (Fig. 1). In this review we first 
describe  the  release  of  adenosine  during  hypoxia/ischemia 
and seizure activity, and then discuss the more recently de-
scribed ways in which these purines can be released.  
EARLY STUDIES OF PURINE RELEASE 
  The  possibility  that  purines  may  be  released  from  the 
CNS emerged in a flurry of activity in the late 1960s and 
early 1970s, primarily led by Henry McIlwain. These early 
studies involved the incorporation and release of 
14C-labelled 
adenine-containing compounds, usually adenine and adeno-
sine.  
  In a pivotal study of 1969, Kakiuchi, Rall and McIlwain 
[91] showed, for the first time, that electrical stimulation of 
guinea pig cerebral cortex resulted in a large (11 fold) in-
crease in tissue cAMP, a compound, which due to the semi-
nal and ultimately 1971 Nobel Prize winning work of Earl 
Sutherland, in  collaboration with Ted Rall,  in the  late 50s 
and early 60s [166,195] had garnered a great deal of interest 
in the neuroscience community. The increase in cAMP was 
greatly attenuated by the adenosine receptor antagonist theo-
phylline,  in  a  manner  related  to  the  duration  of  electrical 
stimulation:  theophylline  had  greater  effect  against  shorter 
durations of stimulation, a finding we would now interpret as 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Sources of extracellular adenosine and ATP. 5'N, cytosolic 5'-nucleotidase; AC, adenylate cyclase; AD adenosine deaminase; AdK, 
adenylate kinase; ADK, adenosine kinase; AL, adenylosuccinate lyase; AS, adenylosuccinate synthase; e5'N, ecto 5'-nucleotidase; eAP, ecto-
alkaline  phosphatase;  ePD,  ecto-phosphodiesterase;  HGPRT,  hypoxanthine  phospho-ribosyl-transferase;  NP,  nucleoside  phosphorylase; 
NPP,  nucleotide  pyrophosphatase/phosphodiesterase;  NTPD,  nucleoside  triphosphate  diphosphohydrolase;  SAHase,  S-adenosyl-L-
homocysteine hydrolase; XO, xanthine oxidase. In red is the primary route of adenosine metabolism and the enzymic cascade utilised by the 
adenosine biosensor. Modified from [148]. 162    Current Neuropharmacology, 2009, Vol. 7, No. 3  Dale and Frenguelli 
due to the competitive nature of theophylline against adeno-
sine receptors. This work led the authors to propose a mecha-
nism  for  the  elevation  of  cAMP  in  which  "….electrical 
pulses exerted their effects by causing the release of active 
endogenous  organic  substances."  and  that  further  studies 
would "…be conducted to test the possibility that the effects 
of electrical pulses involves the release and action of ade-
nine-ribose compounds." In the classic Sattin and Rall study 
of 1970 they conclusively showed that exogenous adenosine 
was capable of stimulating the production of cAMP and that 
methylxanthines could antagonise this effect [180] strength-
ening the possibility that adenosine might be released in re-
sponse to electrical stimulation.  
  An  indication  that  these  prescient  statements  regarding 
the release of purines were to come to fruition was obtained 
the following year in a paper from John Daly's lab [186] in 
which they observed release of adenine-
14C derived radioac-
tivity into the medium surrounding guinea pig cortical brain 
slices. Adenosine was found in greatest quantities (~50 % of 
the radioactivity) with contributions from hypoxanthine and 
inosine. Importantly, the release of adenosine was increased 
by elevated K
+, veratridine and ouabain. Indeed, veratridine 
also  permitted  the  detection  of  small  amounts  of  adenine 
nucleotides in the medium. The authors, based on a proposal 
made  a few years  earlier by Sattin &  Rall, suggested that 
depolarisation induced the release of adenosine and that this 
adenosine then stimulated the production of cAMP. 
  However, it was not until the following year that Henry 
McIlwain reported the release of adenosine, inosine and hy-
poxanthine by electrical stimulation of brain slices and led to 
the proposal of "Synaptic sites of adenosine action?" [130, 
131]. These were followed by a series of full reports further 
characterising  this  observation.  The  first  of  these  [162] 
showed that the 
14C-labelled compounds released, in a stimu-
lation-dependent  manner,  contained  mostly  adenosine,  but 
some inosine, hypoxanthine and nucleotides. This paper also 
showed that oxygen or glucose deprivation also caused the 
efflux of 
14C-labelled derivatives of adenine, which, by ex-
tension to their work with derivatives released by electrical 
stimulation, would likely have included adenosine. The ob-
servations in this paper on adenosine release, and the appre-
ciation of the wider context and implications of these find-
ings  in  "coma  accompanying  hypoglycaemia",  "convulsive 
episodes" and "the neural threshold for excitation" prompted 
the authors to conclude that "Intermediation by adenosine in 
these various processes merits investigation." Some 37 years 
later, this volume testifies that this prediction has certainly 
been fulfilled. 
  Subsequent  studies  from  the  McIlwain  lab  established 
many of the key features of adenosine release that still hold 
sway. For example, his lab noted [163] that basal adenosine 
release was augmented in Ca
2+-free medium, but that evoked 
by electrical stimulation was almost abolished by Ca
2+-free 
medium  and  substantially  inhibited  by  TTX;  that  release 
could be increased by preventing reuptake (with 2'-deoxy-
adenosine  and  papaverine);  inferred  that  adenosine  kinase 
was a major regulator of adenosine release and, on the basis 
of release of adenine derivatives per stimulus being similar 
to that described for ATP by Geoff Burnstock at peripheral 
synapses  [24],  predicted  that  cerebral  adenine  nucleotides 
could  be  released  in  response  to  electrical  stimulation 
[130,161,163].  That  adenosine  and  ATP  release  could  be 
evoked from the intact cerebral cortex by electrical stimula-
tion,  as  demonstrated  by  John  Phillis,  indicated  that  such 
release was not a phenomenon restricted  to isolated  tissue 
preparations [194,223]. 
  The slew of ensuing studies by many other groups on the 
release  of  brain  adenosine  and  ATP  evoked  by  additional 
stimuli such as excitatory amino acids and other transmitters, 
including the methods used to collect and analyse samples, 
have been reviewed by others and provide valuable historical 
and more contemporary accounts [22,112,154,158,215]. 
RELEASE  OF  PURINES  DURING  METABOLIC 
STRESS 
  Evidence obtained by Bob Berne in the early 70s indi-
cated  that  adenosine  accumulated  in  cardiac  and  skeletal 
muscle in response to ischemia. The first description of re-
lease of  adenosine from  the  in vivo brain during  ischemia 
also  came  from  his  lab  [8].  In  this  study  he  and  his  col-
leagues showed that global cerebral ischemia caused an in-
crease in tissue adenosine (as shown earlier by Deuticke and 
Gerlach in  the rat [37]) in both dog and rat brain. Impor-
tantly, they also observed release of adenosine, and the me-
tabolites  inosine  and  hypoxanthine,  into  the  cerebrospinal 
fluid after 6 mins of cerebral ischemia. In attempting to as-
cribe a role to this adenosine release they showed that injec-
tion of adenosine into the carotid arteries increased cerebral 
blood flow in the dog to a small extent whilst topical exoge-
nous adenosine caused marked vasodilatation of pial arteri-
oles in dog and cat (where it was easier to quantify), but in-
jection did not, most likely reflecting breakdown or uptake 
of  exogenous  adenosine.  It  is  interesting  to  note  that  the 
vexed question of whether adenosine arises from "….neural 
cells, glial cells, or from both…" was asked even then.  
PURINE SENSING - THE NEED FOR SPEED 
  An appreciation that changes in the extracellular concen-
tration of purines might influence physiological activity on 
the order of seconds prompted  the  Berne lab to  adopt  the 
innovative "freeze-blowing" technique devised by Veech et 
al., [205] in which high pressure air is blown into one side of 
the cranial cavity via a sharp hollow steel probe and the su-
pratentorial brain expelled via another tube on the contralat-
eral side onto a liquid N2-cooled aluminium plate, thus im-
mediately halting metabolic reactions at defined time points 
on the order of seconds after an intervention.  
  With this technique Dick Winn et al., [219] were able to 
discern changes in tissue adenosine with 5 s of global cere-
bral ischemia following aortic transaction. This allowed the 
authors to conclude that changes in tissue adenosine may be 
sufficiently rapid to regulate cerebral blood flow, a conclu-
sion that has now been widely accepted [70,106,154]. 
  Of course, cerebral vasodilatation is not the only rapid 
consequence of brain hypoxia/ischemia. It has been know for 
many  years  that  cortical  electrical  activity  is  rapidly  sup-
pressed by such insults (reviewed by [103]). Early indica-
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hypoxia/ischemia might occur through the release of adeno-
sine emerged following the seminal studies of John Phillis, 
who showed that exogenous adenosine inhibited cortical and 
cerebellar activity in vivo [102,157] and, with the limitations 
of the drugs and techniques available at the time, observed 
some evidence in vivo of excitation by adenosine antagonists 
caffeine and theophylline [155].  
  Accordingly, Tom Dunwiddie [48] showed conclusively 
that endogenous  adenosine  could  exert effects on synaptic 
transmission in the in vitro hippocampus by demonstrating 
that application of both adenosine deaminase, to metabolise 
extracellular adenosine to inosine, and the adenosine recep-
tor antagonists theophylline and IBMX increased field exci-
tatory postsynaptic (fEPSP) and population spikes, whilst the 
adenosine uptake inhibitor hexobendine inhibited transmis-
sion. Hexobendine had been previously shown by the Daly 
lab, to elevate tissue cAMP levels, indicative of both an ex-
tracellular adenosine tone and adenosine receptors [80]. 
  We now know that these depressant actions of adenosine 
are due to the activation of presynaptic adenosine A1 recep-
tors [16,49,89]. Subsequent work from Brian MacVicar's lab 
suggests  that  this  inhibition  of  glutamatergic  transmission 
involves activation of p38 MAPK cascade [19] and C-Jun  
N-terminal  kinase  [18].  The  extent  to  which  this  pathway 
impacts on the known adenosine-mediated inhibition of Ca
2+ 
spikes  [160]  and  N-  and  P/Q-type  Ca
2+  channels  [14,73, 
134,222,224], which is at least in part membrane-delimited 
and requires βγ subunits, is not yet clear. 
  Putting  the  two  together  -  release  of  adenosine  during 
hypoxia and the inhibition of excitatory synaptic transmis-
sion by hypoxia - did not come about until the early 1980s 
when  a  Society  for  Neuroscience  abstract  appeared  from 
Lipton and Robacker [115,117] indicating that the hypoxic 
depression of hippocampal dentate gyrus population spikes 
was slowed by both IBMX and adenosine deaminase (both 
of which increased the population spike under control condi-
tions). This was not due to better maintenance of tissue ATP 
levels, which had been shown to delay the hypoxic depres-
sion  of  transmission  [116].  In  contrast  IBMX  caused  a 
greater decline in tissue ATP, most likely via greater contin-
ued glutamatergic excitation during the hypoxic episode.  
  A  delay  in  the  hypoxic  depression  of  hippocampal 
fEPSPs by 8-PT was later observed by Dunwiddie and Bertil 
Fredholm, who also observed a late (14 min) rise in adeno-
sine release during hypoxia as measured by HPLC analysis 
of perfusate [63]. This delay in efflux vs effects on synaptic 
transmission has been observed by others using HPLC tech-
niques  [59,60,153],  but  this  is  likely  due  to  low  temporal 
resolution of earlier HPLC studies. Better (2 min) resolution 
showed a clearer correlation between the two [110]. 
  However, by this time, several groups had convincingly 
shown  pharmacologically  that  the  depression  of  synaptic 
transmission caused by hypoxia and combined oxygen/glu-
cose deprivation (OGD, "in vitro ischemia"), in spinal cord 
[122] and in hippocampus [57,58,71], as well as the depres-
sion caused by hypoglycaemia [228] and cyanide [229], were 
dependent on adenosine release and activation of A1Rs. This 
has  been  subsequently  confirmed  in  vivo  for  hypoxia/ 
ischemia [69]. 
  Adenosine  thus inhibits glutamate release during meta-
bolic stress and does not need glutamate receptor activation 
for its release [65,66,149]. It would seem that adenosine may 
be released prior to the release of glutamate and could thus 
delay  potentially  excitotoxic  glutamate  release.  Indeed,  in 
vivo it is clear that this occurs: adenosine is released from the 
cat brain at blood flow levels (~25 ml/100 g/min) higher than 
flow  levels  required  for  glutamate  release  (~20  ml/100 
g/min) [128]. In between this range the electrocorticogram 
(ECoG) was reduced by 80 %, suggestive of a major role for 
adenosine in ECoG suppression. This has recently been con-
firmed  via  the  use  of  A1R  antagonists  which  delayed  the 
ischemic suppression of the ECoG [83]. 
  These observations satisfy Andrew Newby's concept of 
adenosine as a retaliatory metabolite, which he described in 
the following  terms: "Physiologically, adenosine's function 
appears to be to allow a target cell such as the cardiac myo-
cyte to adjust its energy supply and to retaliate against an 
external stimulus which would tend to cause excessive ATP 
breakdown." [138]. It is now clear that not only does adeno-
sine retaliate, it gets its retaliation in first!  
ENZYME-BASED ADENOSINE SENSORS - SENSING 
IN THE FAST LANE 
  Improved correlations between adenosine release during 
hypoxia/ischemia  and  the  inhibition  of  excitatory  synaptic 
transmission  have  been  made  possible  through  the  use  of 
adenosine biosensors, which allow direct, real-time correla-
tions between the two. The first generation biosensors [31] 
relied  upon  a  solution  of  adenosine  metabolising  enzymes 
(adenosine deaminase, purine nucleoside phosphorylase and 
xanthine oxidase) housed within semipermeable microdialy-
sis tubing into which adenosine could diffuse following re-
lease from tissue (Fig. 2). The metabolism of adenosine gave 
rise to hydrogen peroxide which is oxidised on polarised Pt 
or Pt/Ir wire to produce a current proportional to the initial 
concentration of adenosine. Two such sensors, one with the 
full  complement  of  enzymes  and  one  lacking  adenosine 
deaminase, to provide an "inosine" signal, are used in paral-
lel and a differential recording between the two yields a spe-
cific  adenosine  signal,  which  can  both  be  quantified  (via 
calibration  with  exogenous  adenosine)  and  confirmed 
through the use of an adenosine deaminase inhibitor such as 
EHNA or coformycin.  
  The first application of these sensors to mammalian tis-
sue involved them being placed on the surface of hippocam-
pal slices [34] (Fig. 2). During the onset of hypoxia, after a 
brief  transient  negative  deflection,  a  steadily  rising  signal 
was observed on the sensors, which correlated well with the 
depression of the simultaneously-recorded fEPSP, and scaled 
with the duration of hypoxia. Reintroduction of oxygenated 
aCSF caused a decline  in the  adenosine signal  to baseline 
levels. Comparison of the hypoxic fEPSP depression and the 
levels of adenosine as measured at the surface of the slice 
yielded an IC50 of around 3 µM. In this study, the removal of 
Ca
2+  from  the  aCSF  resulted  in  an  increase  in  hypoxic 
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[163], and those of others in hippocampal slices [153] and 
cultured astrocytes [125]. In contrast, elevating extracellular 
Ca
2+ reduced both adenosine release and delayed the hypoxic 
depression of the fEPSP. 
  The basis of this inverse relationship between extracellu-
lar Ca
2+ and adenosine release is not clear, but may reflect 
some  Ca
2+-dependency  of  adenosine  release  or  metabolic 
processes.  Nonetheless,  it  implies  that  at  times  when  ex-
tracellular Ca
2+ is reduced through hypoxia/ischemia [127] 
or in an activity-dependent manner [189], adenosine release 
is facilitated. This has implications for neuroprotection, the 
observed  increase  in  the  tone  and  influence  of  adenosine 
following repetitive synaptic activity [210] and potentially in 
the adenosine-based suppression of seizure activity [46,54].  
ADENOSINE RELEASE - A LABILE PROCESS 
  Given the importance of adenosine as a neuroprotective 
agent  [29,175]  (see  contributions  by  Williams,  Lusardi  & 
Masino, this issue), although this may be developmentally-
regulated [97,202,213], it is somewhat surprising to note that 
the availability of adenosine is not fixed, but labile and de-
pendent on prior adenosine release [148]. This was first de-
scribed in Fredholm's lab [51] where carotid artery occlusion 
in the gerbil resulted in large elevations in response to the 
first  5  min  occlusion,  but  smaller  rises  in  response  to  the 
second.  Similar  observations  were  made  in  the  rat  in  re-
sponse to two 10 mins periods of increased intracranial pres-
sure separated by two hours: the release of cortical adeno-
sine, inosine, hypoxanthine and xanthine were reduced dur-
ing the second [204]. 
  One  functional  implication  of  this  adenosine  depletion 
emerged from a study relating adenosine release to cerebral 
blood flow: in piglets subjected to bicuculline-induced sei-
zures, hypoxia was less effective at inducing cerebral vaso-
dilatation, which could be restored by topical application of 
exogenous  adenosine,  at  non-dilating  concentrations,  sug-
gesting the loss of adenosine during the seizure [38]. That 
adenosine  is  released  during  seizure  activity  is  discussed 
later, but the important point here is that the "pool" of adeno-
sine  recruited  (and  depleted)  by  seizure  activity  and  hy-
poxia/ischemia  are  similar.  Furthermore,  adenosine  release 
in the nucleus tractus solitarius induced by sequential stimu-
lation (100 Hz for 5s) of the hypothalamic defence area re-
sulted in both reduced adenosine release (as measured with 
biosensors)  and  faster  recovery  of  phrenic  nerve  activity, 
indicative  of  reduced  apnoea  [33].  This  observation  may 
underlie the plasticity in behavioural, respiratory and cardio-
vascular components of the hypothalamic defence response 
[126].  
  Subsequent  studies  in  in  vitro  hippocampal  slices  ob-
served similar reductions in extracellular adenosine release 
during repeated hypoxia [65,151,152] and OGD [149], re-
sulting in both reduced depressant effects on synaptic trans-
mission  and  accelerated  recovery  (Fig.  3).  Electrophysi-
ological data obtained recently in vivo involving delays in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Principle behind the MK I adenosine sensor. One barrel of the sensor contains the full complement of enzymes, whilst a second 
lacks adenosine deaminase. The right panel shows the original chart recording of the second ever sensor recording of adenosine release in 
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the time to ECoG suppression during repeated global cere-
bral ischemia and kainic acid-induced seizures are consistent 
with the concept of adenosine depletion following metabolic 
stress [84]. Furthermore, prolonged cerebral ischemia results 
in  waning  adenosine  release  in  vivo  in  cat  cortex  [129], 
whilst in vitro, Ca
2+-free medium resulted in increased adeno-
sine release and exaggerated adenosine depletion [152]. 
  We have postulated [148] that adenosine depletion may 
be injurious to the mammalian brain during repeated or sub-
sequent  insults  to  the  brain  through  both  reduced  cerebral 
vasodilatation and reduced inhibition of excitatory synaptic 
transmission. This is dramatically emphasised by the return 
of the fEPSP to 50% of control 37 mins after the first OGD 
episode and only 15 mins after the second [149] (Fig. 3), and 
may  in  part  account  for  the  increased  vulnerability  of  the 
mammalian brain to repeated insults over 1 - 4 hours [99].  
  The basis of this loss of adenosine is not clear. It may 
involve prolonged depression of ATP levels in the post hy-
poxic/ischemic  state  (eg  [67,100]),  which  may  be  exacer-
bated by  the  loss of downstream metabolites  into the per-
fusate in vitro, and into the systemic circulation, as has been 
observed in humans following cerebral ischemia during ca-
rotid  endarterectomy  [211],  stroke  and  transient  ischemic 
attack [108]. These latter studies raise the interesting possi-
bility  that  adenosine  may  serve  as  a  biomarker  for  acute 
stroke or raised intracranial pressure. 
  However, we have described a number of manipulations 
which either restore hypoxic/OGD release and/or the depres-
sants effects of hypoxia. These include: a) allowing hippo-
campal slices to recover for two hours between episodes; b) 
application of exogenous adenosine; c) application of the β-
adrenoceptor agonist isoproterenol (Fig. 4) [151,152]. These 
observations imply that the "pool" of adenosine can be re-
plenished  with  demonstrable  functional  effects.  Potentially 
this might be exploited for therapeutic benefit in individuals 
vulnerable to repeated or secondary cerebral insults. 
SENSING  BELOW  THE  SURFACE  -  MICROELEC-
TRODE BIOSENSORS 
  Subsequent  refinements  in  sensor  technology  saw  the 
immobilization  of  the  adenosine  metabolising  enzymes  on 
thin (25 - 50 µm) Pt/Ir wire [120] (Fig. 5). This allowed in-
sertion of the sensors into the hippocampal slice and obvi-
ated  concerns  [112]  that  surface  recordings  of  adenosine 
release were somehow influenced by a layer of dead surface 
tissue. Conclusions drawn from the MKII sensors were prac-
tically the same as per surface measurements [65], but addi-
tionally revealed: a) An IC50 of around 1 µM for adenosine 
against the fEPSP during hypoxia; b) a surge of adenosine 
release on reoxygenation; c) hysteresis between the effects of 
adenosine on the fEPSP during the onset and recovery from 
hypoxia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Repeated in vitro ischemia results in reduced adenosine release in hippocampal slices. Upper trace - adenosine release as measured 
by a MK I sensor in response to two sequential periods of oxygen/glucose deprivation (OGD; black bars). Bottom trace - depression and 
recovery of synaptic transmission in response to the OGD episodes. Note the reduced release of adenosine and reduced effects on the fEPSP 
during the second period. Inset are individual fEPSPs taken at the times indicated. Triangles refer to applications of exogenous adenosine to 
test that the sensor has not run down over this period. 166    Current Neuropharmacology, 2009, Vol. 7, No. 3  Dale and Frenguelli 
  Estimates of adenosine concentration in the extracellular 
space range from the tens to low hundreds of nanomolar. The 
lower estimates obtained in  vivo reflect either  cortical cup 
sampling or recovery of tissue damage after insertion of mi-
crodialysis probes [154]. However, attempts to measure ba-
sal adenosine with MKII sensors inserted into hippocampal 
slices have not been conclusive as yet [66]. 
  This may reflect the present requirement of subtracting 
an inosine signal from that of the adenosine sensor to yield a 
net,  differential,  signal.  Subtle  differences  in  extracellular 
adenosine  may  confound  such  spatially-disparate  measure-
ments. An alternative is the application of the ecto-ATPase 
inhibitor ARL 67156 which reduced the adenosine tone by 
around 110 nM [66]. This latter observation is similar to that 
obtained by Dulla et al., using MKI adenosine sensors in the 
presence of ARL 67156 [45] and is consistent with the con-
cept of an adenosine tone being provided by ATP release 
from astrocytes [146]. Estimates of extracellular adenosine 
have been made using pharmacological approaches, (180 – 
240 nM, [111]; 140 – 200 nM; [47]), and HPLC techniques 
(264 nM; [168]) are in agreement with those estimated by 
the sensor using ARL 67156.  
  In  the  cerebellum  the  regulation  of  the  extracellular 
purine  tone  is  unexpectedly  complex  [208].  This  tone  can 
vary  from  one  region  to  another.  Often  the  tone  can  be 
measured (with biosensors) as inosine or hypoxanthine rather 
than as adenosine. Nevertheless an adenosine tone is usually 
apparent as a tonic inhibition of parallel fibre purkinje cell 
synapses. This raises the notion that there may be synaptic 
and non-synaptic extracellular compartments of adenosine. 
  Why these in vitro values of basal adenosine are elevated 
compared to some, but not all, obtained in vivo [154] may 
reflect  the  reduced  recovery  of  adenosine  during  in  vivo 
sampling or the potential for inadequate oxygenation of in 
vitro brain slices [105].  
  Estimates provided by the adenosine sensor for the effi-
cacy of endogenous adenosine against synaptic transmission 
during hypoxia give an IC50 value of around 0.45 - 1.25 µM 
[65,149,151] and values of 20 - 30 µM for peak adenosine 
concentrations achieved during hypoxia/OGD [149]. These 
values are close to those inferred pharmacologically for the 
IC50 of exogenous adenosine against transmission of 600 - 
760  nM  [47],  and  peak  OGD  values  in  vitro  [111],  and 
measured directly, albeit acutely after probe insertion, in vivo 
[51,74].  
  Continuous  sampling  of  extracellular  adenosine  during 
hypoxia  or  OGD  with  adenosine  sensors  inserted  into  the 
hippocampal  slice  have  revealed  two  phases  of  adenosine 
release (Fig. 6): the first is a gradual accumulation during the 
episode and a second, usually much larger surge (the post-
hypoxic/OGD purine efflux; PPE) on reoxygenation [65,66] 
not readily apparent with surface measurements [34,65,149, 
151,152].  This  maybe  due  to  smoothing  of  the  adenosine 
signal along the (horizontal) length of the sensor as opposed 
to sampling from a more restricted quasi-vertical tissue col-
umn when inserted into the slice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Restoration of adenosine release from a hippocampal slice by application of the β-adrenoceptor agonist isoproterenol during the 
second hypoxic period. Right panel, putative scheme by which stimulation of β-adrenoceptors may increase extracellular adenosine (ado). 
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  It  is  interesting  that  this  surge  occurs  when  synaptic 
transmission  is recovering in the slice - giving rise  to  the 
hysteresis we observe between the IC50 of adenosine against 
transmission during the onset and recovery [65,149]. Given 
this, it is unlikely that the function of this surge is to sup-
press  glutamatergic  excitation  in  the  immediate  post-
hypoxic/OGD phase, since this occurs when transmission is 
either severely depressed by prolonged OGD or inhibited by 
omission of Ca
2+ or addition of TTX or glutamate receptor 
antagonists [65]. Instead, this adenosine surge may give rise, 
via A2ARs, to vasodilatation and the hyperemia observed in 
the cerebral circulation in response to hypoxia or ischemia 
[133]. 
  As to why the fEPSP recovers in the face of this large 
surge of adenosine was discussed in detail by Pearson et al., 
[149] where the IC50 for fEPSP suppression during the onset 
of hypoxia was 0.46 µM and increased over 10-fold to 5.7 
µM during the recovery phase. Homologous or heterologous 
desensitisation/inhibition by A1, A2A and A3Rs was ruled out, 
leaving  the  possibility  that  additional  neurotransmitters/ 
modulators may participate in the initial depression phase, 
thereby decreasing the apparent IC50 for adenosine against 
the fEPSP. However, focal deletion [4], knockout [89] and 
pharmacological antagonism [57,58,71] of A1Rs leave little 
scope for additional inhibitory agents during hypoxia/OGD. 
Potentially, microdomains of adenosine, caused by localised 
changes  in  adenosine  release  or  metabolism,  beyond  the 
resolution of adenosine  sensors  may give rise  to this phe-
nomenon. 
ATP RELEASE 
  The release of adenosine during metabolic stress has now 
been investigated in a number of systems and is clearly re-
leased  during  the  very  early  stages  of  hypoxia/ischemia. 
Questions  then  arise  as  to  whether  ATP  is  released  under 
these conditions and whether ATP is the precursor to adeno-
sine. 
  There is pharmacological, immunohistochemical and bio-
chemical evidence that suggests that ATP is released in re-
sponse to ischemia. For example, protein and activity levels 
of some ecto-nucleotidases, the enzymes responsible for the 
extracellular metabolism of ATP [231], were increased post-
ischemia [13] and pharmacological antagonists of P2 recep-
tors  are  generally  protective  under  such  conditions  [62]. 
These  observations  are  consistent  with  ATP  release  in  re-
sponse to cerebral metabolic stress. 
  Attempts have been made to measure ATP release during 
hypoxia/ischemia using microdialysis and cortical cup tech-
niques. In one study hypoxia failed to elevate extracellular 
nucleotide  levels,  despite  a  doubling  of  adenosine  release, 
suggesting that adenosine was released as such and not as a 
nucleotide precursor [159]. However, more severe insults in 
vitro [90] and in vivo [132] have elicited demonstrable ATP 
release from rat hippocampal slices and rat striatum, respec-
tively. These latter studies do not inform as to the temporal 
sequence of release events and whether ATP is released be-
fore adenosine or vice versa. Attempts to resolve this have 
been made in the anoxia-resistant turtle brain [124]. In this 
microdialysis/HPLC/bioluminescence study, both adenosine 
and ATP release was delayed until 60 min after the onset of 
anoxia. The authors felt it unlikely that ATP release contrib-
uted to that of adenosine since the concentration of ATP was 
two orders of magnitude lower than those of adenosine, and 
ATP release was observed to increase during extended an-
oxia whilst the levels of adenosine declined (the latter being 
reminiscent of findings in the mammalian brain). 
  To  address,  with  enhanced  temporal  resolution  the  re-
lease of ATP and adenosine during metabolic stress in the 
mammalian brain, we have recently used ATP sensors [121], 
simultaneously with adenosine sensors, during OGD in hip-
pocampal slices [66]. As per previous findings we observed 
rapid  elevations  in  extracellular  adenosine  coincident  with 
the  depression  of  the  fEPSP.  However,  no  ATP  was  ob-
served during short OGD episodes (Fig. 6A). Furthermore, 
the surge of adenosine on rexoygenation was not accompa-
nied  by  a  rise  in  extracellular  ATP,  suggesting  that  the 
adenosine surge was not dependent on ATP release.  
  In contrast, ATP release was invariably observed when 
the  slice  experienced  the  anoxic  depolarization  (AD;  Fig. 
6B).  Furthermore,  once  the  AD  had  occurred,  ATP  also 
showed a surge on reoxygenation. Thus, from the time just 
prior to the AD, extracellular ATP rose from a low level of 
~100 nM to reach ~700 nM at reoxygenation (some 1 - 2 
mins after the AD) and peaked at 1800 nM during the post-
OGD surge. As might be predicted, the ecto-ATPase inhibi-
tor ARL 67156 potentiated all phases of ATP release, par-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). MK II sensor design (top) and use in hippocampal slices 
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ticularly the post-OGD surge, but had no bearing on adeno-
sine release. 
  ATP release was inseparable from the AD: the AD was 
delayed in younger animals, as was ATP release, whilst the 
AD was accelerated in Ca
2+-free medium, as was ATP re-
lease (Fig. 7). Whole-cell patch-clamp recordings confirmed 
the timing of ATP release vs the AD. An interesting question 
is whether ATP release precedes the AD or vice versa. That 
the  AD  occurs  in  Ca
2+-free/EGTA-  containing  aCSF,  but 
ATP release is prevented (Fig. 7), suggests that the AD pre-
cipitates ATP release and that this release occurs by some 
process with very high affinity for extracellular Ca
2+. Con-
firmation of the relative timing between ATP release and in 
vivo spreading depression has recently been provided by an 
independent group using ATP sensors [182]. In this study 
KCl-induced  spreading  depression  evoked  large  (100  µM) 
ATP transients in rat neocortex. 
  Is this ATP release  a harbinger of impending neuronal 
death? Not necessarily, at least not over the life-time of in 
vitro brain slice studies: ATP release occurred during condi-
tions that would allow the recovery of synaptic transmission 
after in vitro ischemia – eg NMDA receptor antagonism, in 
the presence of TTX and in the absence of extracellular Ca
2+ 
[66]. Thus, ATP release does not necessarily reflect cellular 
lysis, but instead reflects a process activated by, or associ-
ated with, strong (anoxic or spreading) depolarisation. Fur-
thermore, Schock et al., (2007) concluded that ATP release 
and activation of P2 receptors may contribute to protective 
ischemic tolerance [40,41]. In contrast, work from Maiken 
Nedergaard’s  lab  suggests  that  ATP  (measured  in  culture 
using luciferin/luciferase) is released during hypoxic precon-
ditioning which is then metabolised to adenosine (measured 
in culture using adenosine sensors) to initiate the precondi-
tioning cascade via A2BRs in vitro and A1Rs in vivo [114]. 
Regardless of whether ATP or adenosine are  mediators of 
ischemic preconditioning, it is clear that the release of ATP 
may be an important factor in post-ischemic survival of brain 
tissue. 
  In  summary,  the  rapid  hypoxic/ischemic  release  of 
adenosine, and delayed release of ATP, subserve disparate 
functions  in  the  mammalian  brain.  In  terms  of  adenosine 
release, it is likely that this release is important for the inhi-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). MK II sensor measurements of adenosine and ATP release during in vitro ischemia. A) Adenosine release increases gradually dur-
ing the in vitro ischemic episode (black bar) then displays a surge on reoxygenation (black arrowhead). Short episodes of OGD elicit no ATP 
release. B) Longer episodes provoke the anoxic depolarisation and elicit ATP release, which also displays a surge on reoxygenation. Modi-
fied from [66]. Release of Adenosine and ATP During Ischemia and Epilepsy  Current Neuropharmacology, 2009, Vol. 7, No. 3    169 
bition of excitatory synaptic transmission and may contribute 
to the acute neuroprotective efficacy of adenosine [29]. Fur-
ther dilatory actions of adenosine on the cerebrovasculature 
[106] serve to maximise  the delivery of blood to compro-
mised  tissue.  In  contrast,  the  outcomes  of  ATP  release, 
which  may  be  associated  with  spreading-depression,  may 
either have deleterious effects per se, in terms of activation 
of  pore-forming  receptors,  or  may  offset  these  damaging 
consequences through initiation, either directly or indirectly, 
of ischemic preconditioning.  
ADENOSINE  RELEASE  DURING  SEIZURE  ACTIV-
ITY 
  It  has  been  known  for  many  years  that  seizures  cause 
large  decreases  in  cerebral  ATP  [101].  Around  the  time 
when  McIlwain  showed  that  electrical  stimulation  caused 
accumulations of cAMP  and release of  adenosine in brain 
slices,  Sattin  demonstrated  that  seizure  activity  caused  ac-
cumulation of cAMP in brain tissue in vivo [179]. As might 
be expected on the basis of his  earlier work, caffeine and 
theophylline greatly reduced this accumulation, but precipi-
tated more severe seizures - an early indication of the anti-
convulsant  actions  of  endogenous  adenosine.  Subsequent 
work revealed elevations in tissue adenosine in vivo in re-
sponse to electrical stimulation [174], with the expectation 
that it would be released into the extracellular space. 
  Although  rapid  elevations  of  whole  brain  and  cortical 
adenosine  levels  were  observed  during  seizure  activity  in-
duced by electrical stimulation [185] and bicuculline [184, 
220,221],  attempts  by  Schrader  and  colleagues  [184]  to 
measure increased adenosine efflux into the superior sagittal 
sinus  were  unsuccessful.  A  subsequent  HPLC  study  by 
Berne  and  colleagues  did  reveal  increases  in  interstitial 
adenosine following bicuculline-induced seizures in newborn 
piglets,  but  not  when  attempts  were  made  to  increase  the 
oxygen supply to the brain via increased mean arterial blood 
pressure and increased partial pressure of oxygen (pO2) of 
the dialysis perfusate [145]. This suggests that hypoxia asso-
ciated with seizure activity may be an important determinant 
of seizure-induced adenosine release. However, pharmacol-
ogical and adenosine sensor experiments show that adeno-
sine release occurs in vitro in response to very brief (10 - 15 
s) seizures under conditions where oxygenation, of the me-
dium at least, remains constant [54,55]. This does not pre-
clude that there are very localised synaptic changes in oxy-
genation favouring ATP breakdown and adenosine accumu-
lation and release [203]. What may distinguish between the 
two (O2-dependent and O2-independent release) are differen-
tial mechanisms in adenosine release under the two condi-
tions. 
  Adenosine  release  into  the  interstitial  fluid  during  sei-
zures  has  also  been  demonstrated  in  humans  [50].  In  this  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Differential dependency of adenosine and ATP release on extracellular Ca
2+. A) Release of adenosine during in vitro ischemia 
(black bar) is enhanced in nominally Ca
2+-free aCSF, but ATP release is unaffected. B) Addition of EGTA to nominally Ca
2+-free aCSF pre-
vents ATP but not adenosine release. Modified from [66]. 170    Current Neuropharmacology, 2009, Vol. 7, No. 3  Dale and Frenguelli 
seminal  study,  During  and  Spencer  bilaterally  implanted 
microdialysis probes into the hippocampi of 4 patients being 
prepped for ablative surgery for intractable complex partial 
epilepsy.  Measurements  of  adenosine  release  were  made 
over 10 - 16 days during which time at least 3 spontaneous 
seizures were recorded for each patient.  
  Basal adenosine levels, corrected for recovery and 3 - 5 
days after probe insertion, measured 2.33 µM (89 nM uncor-
rected)  in the non-epileptogenic hippocampus and 1.8 µM 
(67 nM uncorrected) in the epileptogenic hippocampus. It is 
tempting to speculate that the lower levels of adenosine in 
the epileptogenic hippocampus reflects astrogliosis-mediated 
increase in adenosine kinase expression and activity, which 
would  lower  extracellular  adenosine  levels  and  also  lower 
seizure threshold [9]. During seizures extracellular adenosine 
rose dramatically in the ipsilateral hippocampus by between 
7.5  and  31-fold,  whilst  in  the  contralateral  hippocampus 
adenosine rose by 5.8 - 8.4 fold. The elevation in the epilep-
togenic hippocampus persisted for 18 mins after the seizure 
which prompted the authors to conclude that adenosine was 
an important factor, not only in seizure termination, but also 
in  the  refractory  period  after  seizures  during  which  the 
threshold for seizures is increased whilst the duration is de-
creased.  Electrophysiological  evidence  for  this  contention 
has been provided and reviewed by significant figures in the 
field  such  as  Dragunow  [42,43]  and  Dunwiddie  [46],  and 
indeed  from  humans  where  caffeine,  aminophylline/theo-
phylline and hyperventilation (see below) are used to pro-
long seizure activity during electroconvulsive therapy [35]. 
  As  an  interesting  historical  footnote,  in  a  final  test  in 
these patients towards the end of the study, the microdialysis 
probe was flushed with 56 mM K
+ for 30 mins, in the pres-
ence and absence of Ca
2+ in the medium. In the presence of 
extracellular  Ca
2+  KCl  evoked  a  large  ~4-fold  increase  in 
adenosine, which was greatly attenuated by the removal of 
Ca
2+.  Ca
2+-free  medium  itself  caused  a  small  increase  in 
dialysate adenosine (from ~60 nM to ~90 nM), reminiscent 
of earlier work indicative of an inhibitory influence of Ca
2+ 
on  adenosine  release.  Subsequent  microdialysis  studies  in 
vivo in rat hippocampus confirmed that seizures evoked by a 
variety of means (bicuculline, kainic acid or pentylenetetra-
zol) caused the release of adenosine, as well as the metabo-
lites inosine, hypoxanthine and xanthine [7].  
  The functions of this adenosine release range from caus-
ing cerebral vasodilatation and ictal hyperemia via A2 recep-
tors [230] and suppression of neuronal excitation via A1 re-
ceptors [46]. 
  In a pharmacological study, we were able to show that 
the  rapid  inhibition  of  the  fEPSP  induced  by  seizures  re-
corded from 600 µm hippocampal slices perfused with Mg
2+-
free  aCSF was due to  the activation of A1 receptors [54]. 
Whereas seizures evoked by brief electrical stimulation (2 s, 
60  Hz)  typically  lasted  for  ~20  s,  the  fEPSP  took  several 
minutes to recover, indicative of a form of post-ictal refrac-
toriness. Although application of an A1R antagonist resulted 
in a doubling of seizure duration and increase in seizure in-
tensity, the inhibition of the fEPSP was greatly attenuated, 
suggesting  an  important  role  for  endogenous  adenosine  in 
seizure suppression and indeed in limiting the spread of sei-
zures as observed in A1R KO mice [56]. In this study we 
were able to show that the activation of A2A and A3Rs had a 
proconvulsant effect through the use of selective antagonists 
which attenuated seizure duration [54]. This raises the possi-
bility that the potential use of A2AR antagonists may extend 
beyond Parkinson's Disease and into seizure disorders [113]. 
  More recently, using adenosine biosensors we have been 
able  to  visualise  directly  the  release  of  adenosine  during 
evoked and spontaneous seizure activity (Fig. 8) [55]. We 
found  that  electrically-evoked  seizures  lasting  ~10  s  were 
associated with the release of ~1 µM adenosine, which re-
mained elevated for around 4 - 5 min, a time course similar 
to the recovery of the fEPSP. Application of the A1R antago-
nist 8-CPT elicited intense spontaneous seizures of around 
50 - 60 s duration and peak adenosine release of 2 µM. Un-
der these conditions extracellular adenosine was elevated for 
prolonged periods, most likely reflecting frequent spontane-
ous seizures and increased interictal activity. 
ATP RELEASE DURING SEIZURES 
  Of  course,  as  per  hypoxic/ischemic  adenosine  release, 
these observations of adenosine release during seizure activ-
ity beg the question as to whether or not ATP is released as a 
precursor to adenosine. 
  Early indications that adenine nucleotides were released 
by  depolarisation  and  electrical  stimulation  of  brain  slices 
[78,163,186] were given a boost in the mid 1970s following 
the  introduction  of  a  luciferin-luciferase  technique  for  the 
direct demonstration of ATP release [86]. In this preparation, 
an extract of firefly lanterns was dripped over slices of the 
electric organ of Torpedo marmorata, against which a pho-
tomultiplier tube was pressed. Electrical stimulation of the 
electric nerve resulted in  increases  in emitted  light, which 
could be blocked by curare and potentiated by eserine. Using 
this  technique Thomas White showed the direct release of 
ATP from a synaptosomal preparation in response to stimu-
lation by KCl and veratridine, the former of which was sensi-
tive  to extracellular  Ca
2+, whilst the latter was blocked by 
TTX [214]. 
  Evidence that ATP release occurred in response to elec-
trical stimulation in vivo was obtained by John Phillis from 
somatosensory  cortex  using  luciferin-luciferase.  In  these 
experiments, ATP release was not sampled on-line, but sam-
ples from the cortical cup were taken at intervals and showed 
large elevations in ATP in response to direct stimulation of 
the cortex [223]. These studies were extended by Wieraszko 
et al., who used luciferin-luciferase to reveal the direct re-
lease of ATP during stimulation of the Schaffer pathway in 
hippocampal slices, which was Ca
2+ dependent, but not de-
pendent  on,  or  induced  by,  glutamate  receptor  activation, 
suggesting presynaptic release of ATP [216]. 
  Notwithstanding the concerns of Hamann and Attwell of 
ATP release  caused by stimulation-induced electroporation 
of axons [76], these studies showing the release of ATP in a 
manner consistent with neurotransmitters presaged the dem-
onstrations of synaptic currents mediated by ATP in medial 
habenula [52], hippocampus [135,142] and neocortex [143] 
and  in  other  structures  such  as  locus  coeruleus  [139]  and 
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Indeed, a vesicular ATP transporter (VNUT1) has recently 
been described [181]. These observations suggest that there 
may be an ATP and P2 component in the neuronal hyperex-
citability of seizure states, but this has not been conclusively 
addressed. 
  There have been suggestions that ATP is proconvulsant 
via  P2X  receptors,  since  the  excitatory  actions  of  α,  β-
meATP  in  a  low  Mg
2+/4-AP  hippocampal  slice  model  of 
seizure activity was reduced by suramin and PPADS [173]. 
This is consistent with the presence and stimulatory actions 
of  P2X  receptors  (P2X1,  P2X2/3,  and  P2X3)  on  glutamate 
release in hippocampal synaptosomes, whereas P2Y1, P2Y2, 
and  P2Y4  receptors  inhibit  glutamate  release  [171].  Under 
these conditions the enhanced release of ATP, as determined 
with luciferin-luciferase, in seizure prone DBA/2 mice [217], 
might contribute to seizure propensity, as might upregulation 
of P2X7 receptors [206], although this latter observation is 
not universal [94]. 
  In contrast, down-regulation of P2X2 and P2X4 receptors 
have been described in seizure-sensitive gerbil hippocampus 
[93],  as  has  a  decrease  in  evoked  ATP  release  in  kindled 
hippocampal  synaptosomes  [168].  Changes  in  the  evoked 
release of ATP in seizure states are reflected in alterations in 
ecto-nucleotidase activity [10,11,137,140,168,183], although 
these may be developmentally-regulated [36]. A number of 
recent  reviews  cover  the  potential  role  of  ATP  in  seizure 
activity [61,107]. 
  A  recent  publication  suggested  that  the  release  of  en-
dogenous ATP and adenosine is influenced by extracellular 
pH  (pHe)  [45],  which  is  known  to  change  during  seizure 
activity [187]. In this study, hypercapnia (10 - 20 % CO2) 
caused pHe to drop and a depression of the fEPSP. This was 
associated  with  an  increase  in  extracellular  adenosine,  as 
measured with MKI sensors on the surface of the slice. The 
depression  of  transmission  was  mediated  in  part  by  both 
A1Rs  and  P2  receptors  since  only  the  combination  of 
DPCPX (A1Rs) and PPADS (P2Rs) fully prevented the inhi-
bition  of  the  fEPSP.  Conversely,  hypocapnia  (2  %  CO2), 
which caused tissue alkalosis, resulted in an enhancement of 
the fEPSP. This enhancement was mostly occluded by the 
excitation produced by A1R antagonism. However, a small 
excitatory role for P2Rs was also discerned under these con-
ditions. Similar observations on hypercapnia were made in 
spinal cord, although intracellular acidification was consid-
ered responsible for the release of adenosine [141]. 
  That CO2 levels might have a bearing on seizure activity 
is evidenced by the fact that hyperventilation, which reduces 
CO2 and induces hypocapnia, is used to prolong electrocon-
vulsive seizures [35] and to elicit absence, ie thalamocorti-
cal, [136] and temporal lobe seizures [72] in vulnerable indi-
viduals. Accordingly, Dulla et al., [45] showed that hypo-
capnia (2 % CO2) caused a decrease in extracellular adeno-
sine  and  an  increase  in  interictal  burst  frequency  in  area 
CA3, which was occluded by DPCPX and the P2 antagonist 
suramin. Thus, certain forms of seizures may have a strong 
purinergic  component  manifest  by  the  interaction  of  both 
adenosine and ATP. Subsequent studies with microelectrode 
ATP biosensors may reveal this putative ATP component. 
MECHANISMS OF PURINE RELEASE 
  The  question  as  to  how  and  from  where  the  purines 
adenosine and ATP are released is complex. The answer will 
depend critically upon the nature of the stimulus and may 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Release of adenosine during A) brief electrically-evoked seizures and B) spontaneous seizures in the presence of the A1R antagonist 
CPT. Periodic downward deflections reflect fEPSPs evoked at 15 s intervals. Following seizure activity the fEPSP is transiently depressed - 
less so in CPT, despite a much longer seizure. Modified from [55]. 172    Current Neuropharmacology, 2009, Vol. 7, No. 3  Dale and Frenguelli 
potentially involve multiple temporally- and spatially-over-
lapping sources from several cellular sites. This is especially 
the case for adenosine and ATP given their ubiquitous distri-
bution across all cell types.  
  Having  said  that,  an  important  role  of  astrocytes  in 
adenosine release during hypoxia/OGD has been suggested 
through  the  use  of  pure  astrocyte  cultures,  which  release 
adenosine during hypoxia/OGD, or  the gliotoxin fluorocit-
rate in hippocampal slices, which prevented the hypoxic de-
pression of the fEPSP to a similar extent to the A1R antago-
nist CPT, suggesting that intact glial metabolism is required 
for adenosine release during hypoxia [125]. In a similar vein, 
the acute depression of synaptic transmission by the fluoro-
citrate precursor fluoroacetate was reversed by A1R antago-
nism [26]. 
  However, the mechanism by which hypoxic/OGD adeno-
sine release occurs is not clear. For example, inhibition of 
equilibrative nucleoside transporters (ENTs; [98]) with cur-
rently-available drugs does not prevent the release of adeno-
sine  during  hypoxia/OGD  in  vitro  [66,125,152]  (and  may 
indeed potentiate release), a condition where one might rea-
sonably expect the elevation of intracellular adenosine to be 
expelled via ENTs. 
  Alternatively,  additional  mechanisms  of  purine  efflux 
exist that have been described since the initial descriptions of 
vesicular- and transporter-mediated release, which may play 
profound roles in regulating the availability of extracellular 
adenosine. Given that a considerable body of literature exists 
on  "traditional"  purine  conduits  [49,68,112,215],  we  now 
focus our attention on more recent additions to the panoply 
of purine release mechanisms. 
REVISITING  THE  MECHANISMS  OF  ADENOSINE 
RELEASE: 
Exocytosis 
  A common consensus is that adenosine arises in the ex-
tracellular space  either  through the breakdown of ATP, or 
through the action of equilibrative transporters. Nevertheless 
there is mounting evidence for other mechanisms of adeno-
sine release some of which resemble exocytotic release (see 
[210] for a review). 
  In  the  cerebellum  adenosine  release  can  be  evoked  by 
brief tetanic stimulation of the parallel fibres by a mecha-
nism  that  is  both  Ca
2+-dependent  and  TTX-sensitive,  two 
common hallmarks of exocytotic release [209]. This release 
of adenosine occurs in the apparent absence of ATP release, 
cannot  be  altered  by  compounds  that  inhibit  ectonucleoti-
dases, is insensitive to transport inhibitors and does not de-
pend on activation of glutamate receptors. The likeliest ex-
planation is that it represents release of adenosine from vesi-
cles. Nevertheless, this a controversial conclusion and further 
definitive evidence is required to eliminate the possibility of 
any other type of mechanism before the notion of exocytotic 
release of adenosine will gain widespread acceptance. 
Retrograde Signalling 
  An interesting concept proposed by Tom Dunwiddie was 
that  adenosine  could  be  released  from  neurones  in  an  an-
tidromic fashion, from the postsynaptic dendrite to the pre-
synaptic  terminal,  thereby  regulating  neurotransmitter  re-
lease in response to postsynaptic activity. This suggestion of 
retrograde  signalling  presaged  the  explosion  of  interest  in 
retrograde signalling by endocannabinoids and other trans-
mitters such as GABA and glutamate. Brundege and Dun-
widdie [15] showed that loading postsynaptic CA1 pyrami-
dal neurones with exogenous adenosine resulted in a larger 
suppression of synaptic transmission, as defined by the grea-
ter effects of adenosine receptor antagonists and adenosine 
deaminase  on  synaptic  transmission,  and  a  raised  paired-
pulse facilitation ratio. However, attempts to elevate endoge-
nous adenosine in single neurones sufficiently to influence 
synaptic  function  were  not  successful  [17].  Nonetheless, 
these studies leaving open the tempting suggestion that neu-
ronal  or  glial  retrograde  signalling  by  adenosine  or  ATP 
[85,178] might still be a fruitful avenue to pursue in hippo-
campus and other brain regions [77]. 
MECHANISMS OF ATP RELEASE 
  While ATP is undoubtedly present in, and released from, 
vesicles  through  exocytosis  [3,144],  channel-mediated  re-
lease also seems to be important under certain circumstances. 
Release Through Gap Junction Hemichannels 
  There  are  two  gene  families  capable  of  forming 
hemichannels and gap junctions (the docking of hemichan-
nels  in  two  opposed  membranes  to  form  an  intercellular 
pathway): the connexins and pannexins [188]. Pannexins are 
homologous to the invertebrate innexins. Gap junctions are 
well  known  to  be  permeable  to  molecules  of  a  molecular 
weight of up to around 1000. Thus the idea that ATP and 
other small metabolites could permeate gap junctions has a 
long history. However, for a long time it was not apparent 
that hemichannels had any physiological role. 
  The first suggestion that hemichannels could be impor-
tant in their own right came from studies on cultured astro-
cytes,  which  suggested  a  role  for  Cx43-mediated  ATP  re-
lease in the propagation of Ca
2+ waves elicited by mechani-
cal stimulation [191,192]. Nevertheless there was resistance 
to the idea that hemichannels could gate open under normal 
circumstances.  Further  reports  followed  demonstrating 
hemichannel-mediated ATP release in the developing cortex 
[212] and retina [147], increasing acceptance of the idea that 
hemichannels  could  release  ATP  under  physiological  cir-
cumstances. Hemichannel mediated-ATP release and associ-
ated P2Y receptor-generated Ca
2+ signalling seems to be a 
common mechanism in several developmental contexts [32]. 
However, neither A1R nor P2Rs seem to participate in astro-
cytic Ca
2+ waves that develop over a period of an hour fol-
lowing photothrombosis-induced ischemia [39].  
  Elegant  studies  from  Nedergaard’s  group  have  demon-
strated directly ATP release through Cx43 hemichannels in 
isolated membrane patches [92]. As astrocytes possess Cx43 
hemichannels this leaves open the possibility that astrocytes 
can release ATP by this route, but this is controversial. For 
example  Bowser  and  Khakh  [12]  present  evidence  that 
propagating  Ca
2+  waves  in  astrocytes  occur  via  exocytotic 
release of ATP, which is consistent with the evidence from 
Pascual et al., [146] which suggests that ATP release from 
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sion. Interestingly, a small delay in the initial hypoxic de-
pression  of  the  fEPSP  was  observed  in  dominant-negative 
SNARE  mice  suggesting  a  contribution  of  this  process  to 
extracellular  adenosine  during  the  early  stages  of  hypoxia 
[125]. Nevertheless Cx43-mediated ATP release from astro-
cytes could play a role in pathophysiological events such as 
responses to hypoxia [114] (however see [66] and [125] and 
below for countervailing views).  
  Meanwhile, Dahl and colleagues found that pannexin-1 
could form ATP-permeable hemichannels. Initially this was 
demonstrated  as  a  response  to  mechanical  stimulation  [5]. 
These  authors  also  found  that  pannexin-1  gating  could  be 
modulated by intracellular Ca
2+ [123] and that ATP could act 
back to inhibit pannexin-1 gating [164]. Evidence that ATP 
release through pannexin-1 hemichannels can be of physio-
logical significance comes from the demonstration that they 
release  ATP  from  taste  receptor  cells  to  activate  afferent 
transmission [81,172].  
  Thompson et al., [199] demonstrated that large conduc-
tance channels open in hippocampal neurons during OGD. 
As these channels were permeable to fluorescent dyes and 
could be blocked by hemichannel inhibitors they suggested 
that  the  channels were hemichannels, possibly pannexin-1. 
This pannexin channel gating could give rise to ATP release. 
However Frenguelli et al., [66] demonstrated that ATP re-
lease during OGD was insensitive to carbenoxolone, an ef-
fective blocker of connexin and pannexin hemichannels, and 
Martin et al., [125] were similarly unable to block adenosine 
release with the gap junction blockers flufenamic acid and 
18α-glycyrrhetinic  acid.  Nonetheless,  connexion  gap  junc-
tions  and  hemichannels  have  been  implicated  in  ischemic 
cell death [28,169]. 
  Pannexin-1  hemichannels  are  present  in  pyramidal  cell 
dendrites. Their gating, triggered by NMDA receptor activa-
tion, contributes to seizure generation in hippocampal neu-
rons [198] raising the possibility that ATP release via this 
route could play a role in epileptiform activity.  
Other Ion Channels 
  A range of other channels have been postulated as con-
duits  for  ATP  release  (reviewed  by  Sabirov  and  Okada 
[177]).  These  include-volume  activated  anion  channels, 
CFTR, the maxi anion channel [176] and the P2X7 receptor 
itself [193]. However, the P2X7 receptor does not seem to 
contribute to hypoxic adenosine release from cultured astro-
cytes [125] and the volume-activated anion channel blockers 
tamoxifen and DNDS did not affect the (largely adenosine-
dependent) hypoxic depression of the fEPSP [150]. 
  The difficulty in this field is that many of the pharmacol-
ogical tools required to identify the involvement of particular 
channels lack useful selectivity to discriminate between them 
[190]. A range of experimental data  is required, including 
direct measurement through patch clamp recording of ATP-
permeant  channel  gating  and  the  use  of  genetic  methods, 
such as siRNA knockdown, to confirm definitively the mo-
lecular identity of the channel. 
  The  evidence  for  ATP-permeation  of  the  maxi-anion 
channel  is  particularly  convincing  [176].  Recent  evidence 
implicates this channel in the release of ATP from cultured 
astrocytes  during  osmotically  induced  swelling  [119]  and 
OGD [118]. Whether this pathway of ATP release is signifi-
cant in vivo remains to be determined. 
  In summary there are many competing claims with regard 
to  the  mechanisms  of  ATP  release  from  cells.  There  are 
likely to be multiple pathways by which ATP is released and 
this complexity of release may be especially evident under 
pathophysiological  conditions.  Nevertheless,  simplification 
of our understanding of ATP release may arise from the rig-
orous use of more selective pharmacological tools and ge-
netic methods to dissect the relevant pathways. 
FUTURE PERSPECTIVES 
Future Developments in Purine Sensing 
  The MKI sensor [31] was an advance in terms of tempo-
ral  and  spatial  resolution  of  extracellular  adenosine  meas-
urements.  Even  then  (late  1990s/early  2000s)  it  was  clear 
that there was a need for greater spatial and temporal resolu-
tion, as well as the requirement for sensing within, as op-
posed to from the surface, of tissue. Many of these issues 
were  addressed  by  the  MKII  microelectrode  sensors  [120, 
121]. However, particularly with the explosion of interest in 
neuroglial signalling, there is a desire to make measurements 
from individual cells and potentially from individual release 
sites. That these high spatio/temporal requirements may be 
met  by  future  developments  in  sensor  design  is  a  distinct 
possibility thereby providing devices that can be placed ad-
jacent to cells/release sites to register the release of minute 
quantities of purines and other transmitters. Parallel devel-
opments in fast cyclic voltammetry of adenosine [27,82,197] 
may yield sub-second temporal resolution for adenosine as it 
has done for dopamine [218]. Genetics may provide a means 
of targeting purine-responsive proteins to specific cells and 
sites. These proteins, engineered to respond to extracellular 
adenosine, ATP and other neuroactive compounds, through 
changes  in fluorescence intensity or wavelength, may pro-
vide the ultimate in spatial and temporal resolution.  
Future Developments in Purine Signalling 
  Purine research has matured enormously in the past 80 
years - so much so that it now has an 'ome of its own - the 
Purinome [207]. However, many issues remain outstanding - 
including the cellular sources and mechanisms of purine re-
lease under conditions - for example seizures and ischemia - 
that likely recruit a panoply of cell types and purine conduits. 
Thus,  we  are  further  forward  in  defining  cells  capable  of 
mediating  release  and  novel  release  mechanisms,  but  the 
temporal sequence and relative contribution of each has yet 
to be determined. 
  This  information  is  important  if  we  are  to  harness  the 
enormous potential of the Purinome as a therapeutic target: 
directing  enhanced adenosine release  to specific areas,  via 
adenosine kinase inhibition for example, may promote pro-
tection via P1 receptors, whilst discerning protective vs dam-
aging aspects of P2 receptors may yield specific targets for 
selective intervention in a range of acute and chronic neuro-
logical conditions. 
  Such  an  understanding  will  however  only  come  about 
through  greater  insight  into  the  complexities  of  purinergic 
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selective agonists and antagonists, particularly for P2 recep-
tors, 2) selective blockers of the myriad conduits for the re-
lease  of  adenosine,  ATP  and  other  endogenous  purinergic 
agonists and 3) electrochemical and genetic techniques with 
high  spatio-temporal  resolution  for  the  release  of  purines 
from discrete cellular locations. 
  Realising many of these challenges is within sight: purine 
research has had a welcome shot in the arm through the role 
of purines in gliotransmission, connexins/pannexins as purine 
channels, and the realisation that the widespread (side) ef-
fects of purines described by Drury & Szent-Györgyi can be 
circumvented,  creating  a  growing  base  of  purine-based 
medicines [23,87]. The ensuing influx of new investigators 
bring  with  them  new  techniques,  new  questions  and  new 
demands, which will hopefully be met by parallel advances 
in pharmacology, optogenetics and amperometry.  
  The future has never looked brighter for purinology. Let's 
hope that the next eighty years see as remarkable advance in 
our understanding as the previous eighty have. 
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